ArticleKorean journal of pediatrics2012
Mycoplasma pneumoniae pneumonia in children.
Article in Korean journal of pediatrics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Efficacy of glucocorticoids for the treatment of macrolide refractory mycoplasma pneumonia in children: meta-analysis of randomized controlled trials.BMC pulmonary medicine · 2019Pooled it
- Real-Time PCR and Quantitative Culture forBioMed research international · 2020Trial
- Systemic Corticosteroids in Pediatric Community-Acquired Pneumonia: Evidence, Clinical Outcomes, and Phenotype-Based Therapeutic Considerations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Clinical role of miR-1271-5p in severe pediatric pneumonia and its prognostic value.BMC immunology · 2026Article
- A retrospective analysis of 266 cases: clinical features of Chlamydia pneumoniae pneumonia in children.BMC infectious diseases · 2026Article
- Taming the Inflammation: The Role of Corticosteroids in Pediatric Mycoplasma Pneumonia.Children (Basel, Switzerland) · 2026Review
- A new immunological paradigm for diseases: the protein-homeostasis-system hypothesis.Frontiers in immunology · 2026Review
- Article
- Co-detection of respiratory pathogens in children withFrontiers in pediatrics · 2025Article
- Whole-genome probe capture sequencing reveals genomic diversity and characteristics ofFrontiers in microbiology · 2025Article
- Atypical pneumonia (Review).Experimental and therapeutic medicine · 2024Review
- The molecular characteristics, diagnosis, and treatment of macrolide-resistantFrontiers in pediatrics · 2023Review
- Global Coinfections with Bacteria, Fungi, and Respiratory Viruses in Children with SARS-CoV-2: A Systematic Review and Meta-Analysis.Tropical medicine and infectious disease · 2022Review
- Analysis of national surveillance of respiratory pathogens for community-acquired pneumonia in children and adolescents.BMC infectious diseases · 2022Article
- The investigation of P1 gene inNew microbes and new infections · 2022Article
- The value of interleukin-27 for differentiating tuberculous pleural effusion fromFrontiers in pediatrics · 2022Article
- Ribosomal RNA‑depleted RNA sequencing reveals the pathogenesis of refractoryMolecular medicine reports · 2021Observational
- Multiple anatomic sites of infarction in a pediatric patient with M. pneumoniae infection, a case report.BMC pediatrics · 2021Article
- Macrolide-Resistant and Macrolide-SensitiveJournal of clinical medicine · 2021Article
- Clinical characteristics of refractory mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy.BMC infectious diseases · 2021Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae (MP), the smallest self-replicating biological system, is a common cause of upper and lower respiratory tract infections, leading to a wide range of pulmonary and extra-pulmonary manifestations. MP pneumonia has been reported in 10 to 40% of cases of community-acquired pneumonia and shows an even higher proportion during epidemics. MP infection is endemic in larger communities of the world with cyclic epidemics every 3 to 7 years. In Korea, 3 to 4-year cycles have been observed from the mid-1980s to present. Although a variety of serologic assays and polymerase chain reaction (PCR) techniques are available for the diagnosis of MP infections, early diagnosis of MP pneumonia is limited by the lack of immunoglobulin (Ig) M antibodies and variable PCR results in the early stages of the infection. Thus, short-term paired IgM serologic tests may be mandatory for an early and definitive diagnosis. MP infection is usually a mild and self-limiting disease without specific treatment, and if needed, macrolides are generally used as a first-choice drug for children. Recently, macrolide-resistant MP strains have been reported worldwide. However, there are few reports of apparent treatment failure, such as progression of pneumonia to acute respiratory distress syndrome despite macrolide treatment. The immunopathogenesis of MP pneumonia is believed to be a hyperimmune reaction of the host to the insults from MP infection, including cytokine overproduction and immune cell activation (T cells). In this context, immunomodulatory treatment (corticosteroids or/and intravenous Ig), in addition to antibiotic treatment, might be considered for patients with severe infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.